Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Study indicates ISIS-3521/CGP-64128A inhibits tumor growth

Aug. 23, 1996

IDEC-Y2B8/IDEC-C2B8 combination undergoes phase I/II

Aug. 23, 1996

Fareston launched in the U.K.

Aug. 23, 1996

Phase I pharmacokinetic study of asulacrine initiated

Aug. 23, 1996

Japanese investigators describe antileukemia activity of drupangtonine

Aug. 23, 1996

Taiho discloses antitumor nucleoside drugs

Aug. 23, 1996

Somatix in-licenses Salk gene transfer technology

Aug. 16, 1996

StressGen licenses cancer gene therapy technology from MRC

Aug. 16, 1996

Somatix issued patent on glioma gene therapy

Aug. 16, 1996

Advanced Therapies, Genetic Therapy collaborate on gene therapy

Aug. 16, 1996

Popular Stories

NIH changes set industry up for workforce, ideas drought
BioWorld
On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...
Today's news in brief
BioWorld
BioWorld briefs for March 14, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for March 14, 2025
At CROI, HIV cure trials raise hopes for broader applicability
BioWorld
At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...
Hummingbird migrates ADCs, tech to newco Callio’s $187M debut
BioWorld
Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...